Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results
Authors:
Open Access
- 20 June 2006
- journal article
- review article
- Published by Springer Nature in British Journal of Cancer
- Vol. 95 (2) , 139-145
Abstract
Cyclooxygenase-2 (COX-2) is overexpressed in lung cancer, especially in adenocarcinoma (ADC). Our aim was to determine the prognostic value of COX-2 on survival in patients with lung cancer. Studies evaluating the survival impact of COX-2 in lung cancer, published until December 2005, were selected. Data for estimation of individual hazard ratios (HR) for survival were extracted from the publications and combined in a pooled HR. Among 14 eligible papers, all dealing with non-small-cell lung cancer, 10 provided results for meta-analysis of survival data (evaluable studies). Cyclooxygenase-2 positivity was associated with reduced survival, improved survival or no statistically significant impact in six, one and seven studies, respectively. Combined HR for the 10 evaluable studies (1236 patients) was 1.39 (95% confidence intervals (CI): 0.97–1.99). In stage I lung cancer (six evaluable studies, 554 patients), it was 1.64 (95% CI: 1.21–2.24). No significant impact was shown in ADC. A slight detrimental effect on survival in patients with lung cancer is associated with COX-2 expression, but the statistical significance is not reached. This effect is statistically significant in stage I, suggesting that COX-2 expression could be useful at early stages to distinguish those with a worse prognosis.Keywords
This publication has 53 references indexed in Scilit:
- Chemotherapy Induces the Expression of Cyclooxygenase-2 in Non–Small Cell Lung CancerClinical Cancer Research, 2005
- Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancerLung Cancer, 2005
- Co-expression of Cox-2 and EGFR in stage I human bronchial adenocarcinomasLung Cancer, 2004
- Neuroendocrine and biologic features of primary tumors and tissue in pulmonary large cell carcinomasThe Annals of Thoracic Surgery, 2004
- COX-2, MMP-9, and Noguchi Classification Provide Additional Prognostic Information About Adenocarcinoma of the LungAmerican Journal of Clinical Pathology, 2004
- Regulation of Cyclooxgenase-2 mRNA Stability by TaxanesJournal of Biological Chemistry, 2003
- Cyclooxygenase‐2: A novel molecular target for the prevention and treatment of head and neck cancerHead & Neck, 2002
- Expression of cyclooxygenase‐1 and cyclooxygenase‐2 in bronchial epithelium and nonsmall cell lung carcinomaCancer, 2002
- Cyclooxygenase‐2 (COX‐2) mRNA Expression Levels in Normal Lung Tissues and Non‐small Cell Lung CancersJapanese Journal of Cancer Research, 1999
- Beta blockade during and after myocardial infarction: An overview of the randomized trialsProgress in Cardiovascular Diseases, 1985